Perspective Therapeutics (CATX) Cash & Equivalents (2010 - 2026)

Perspective Therapeutics (CATX) has 17 years of Cash & Equivalents data on file, last reported at $270.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents rose 27.96% year-over-year to $270.9 million; the trailing twelve-month figure through Mar 2026 stood at $270.9 million (up 27.96% YoY), and the FY2025 full-year result was $30.6 million, down 50.26% from the prior year.
• Cash & Equivalents advanced to $270.9 million in Q1 2026, from $30.6 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $270.9 million in Q1 2026 to a low of $9.2 million in Q4 2023.
• A 5-year average of $100.1 million and a median of $55.9 million in 2022 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents soared 1389.18% in 2024 and slumped 90.01% in 2025, its largest moves.
• Tracing CATX's Cash & Equivalents over 5 years: stood at $21.0 million in 2022, then sank by 55.99% to $9.2 million in 2023, then surged by 566.59% to $61.6 million in 2024, then sank by 50.26% to $30.6 million in 2025, then soared by 784.46% to $270.9 million in 2026.
• Business Quant data shows CATX's Cash & Equivalents at $270.9 million in Q1 2026, $30.6 million in Q4 2025, and $26.8 million in Q3 2025.